Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eng, P. M.
Right arrow Articles by Seeger, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eng, P. M.
Right arrow Articles by Seeger, J. D.
Related Collections
Right arrow MRI
Right arrow All Immunology
Right arrow HIV
NEUROLOGY 2006;67:884-886
© 2006 American Academy of Neurology
Brief Communications

Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population

P. M. Eng, ScD, B. R. Turnbull, MSc, S. F. Cook, PhD, J. E. Davidson, MPH, T. Kurth, MD, ScD and J. D. Seeger, PharmD, DrPH

From i3 Drug Safety (P.M.E., B.R.T., J.D.S), Auburndale, MA; GlaxoSmithKline (S.F.C., J.E.D.), Research Triangle Park, NC, and Harlow, UK; Divisions of Aging and Preventive Medicine (T.K.), Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Department of Epidemiology (T.K., J.D.S.), Harvard School of Public Health, Boston, MA.

Address correspondence and reprint requests to Dr. P. Mona Eng, i3 Drug Safety, Riverside Center, 3-120, 275 Grove Street, Auburndale, MA 02466; e-mail: meng{at}epidemiology.com

Based on health insurance claims from a large U.S. health insurer, the authors identified 44 progressive multifocal leukoencephalopathy (PML) cases from 2002 through 2004 and described their characteristics, including antecedent diagnoses and treatments as well as survival. Immunosuppressive conditions such as HIV/AIDS, rather than potentially immunosuppressive treatments, were the main antecedents of PML. A lower mortality was observed among PML patients whose antecedent diagnosis was HIV/AIDS, the majority of whom received highly active antiretroviral therapy.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the September 12 issue to find the title link for this article.

Funded by a research contract from GlaxoSmithKline.

Disclosure: The role of GlaxoSmithKline was limited to the study design and review of the manuscript. An author disclosure form has been completed by each co-author. All co-authors agree to the conditions of the author disclosure form. Drs. Eng and Seeger and Mr. Turnbull are full-time employees of Ingenix, a subsidiary of UnitedHealth Group. Dr. Cook and Ms. Davidson are full-time employees of GlaxoSmithKline, the company that supported this study, and received personal compensation (salary) in excess of $10,000 during the course of this study and have equity of value less than $10,000 in GlaxoSmithKline.

Received January 23, 2006. Accepted in final form April 26, 2006.




This article has been cited by other articles:


Home page
 Arch DermatolHome page
B. D. Korman, K. L. Tyler, and N. J. Korman
Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression: A Cautionary Tale for Dermatologists
Arch Dermatol, August 1, 2009; 145(8): 937 - 942.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.